Refactor Capital is an early-stage venture capital firm that invests in founders solving fundamental human problems.
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A
Portfolio 96
| Date | Name | Website | Total Raised | Location |
| 03.05.2025 | Pilgrim | pilgrimlabs.com | - | - |
| 03.05.2025 | getcausal.ai | - | - | |
| 03.05.2025 | Hexium | hexium.us | - | - |
| 03.05.2025 | reel.bio | - | - | |
| 03.05.2025 | Remedy Sci... | remedyscientific.com | - | - |
| 03.05.2025 | Pila Energ... | pilaenergy.com | - | - |
| 03.05.2025 | Biological... | bbb-tech.com | - | - |
| 31.12.2024 | Granza Bio... | granzabio.com | $7M | - |
| 31.12.2024 | Vitra Labs | vitra.bio | - | United Sta... |
| 31.12.2024 | Biobot Ana... | biobot.io | $67.04M | United Sta... |
Show more
Mentions in press and media 24
| Date | Title | Description |
| 06.02.2025 | Miist Therapeutics: Breathing New Life into Medicine with $7M Funding | In the bustling world of healthcare innovation, Miist Therapeutics stands out like a lighthouse in a storm. The Alameda, California-based company has just secured $7 million in seed funding, a financial boost that promises to propel its gro... |
| 05.02.2025 | Miist Therapeutics Raises $7M to Develop Inhaled Medicines with Physics-Based Approach | What You Should Know: – Miist Therapeutics, a pioneering company developing inhaled medicines with a focus on rapid drug delivery raises $7M ina seed funding round led by Refactor Capital with participation from 1517 Fund, Freeflow Ventures... |
| 22.04.2024 | General Galactic emerges from stealth to make methane from carbon dioxide | Plenty of products benefit from tight integration, where companies design and sometimes build key components of a product in-house: Apple and its custom microprocessors and Tesla and its Superchargers are two notable examples. It’s not an e... |
| 13.03.2024 | IVF uncertainty aside, startups rush to offer fertility care amid rising demand | AI tools, egg freezing, surrogacy, IUI, donorship, oncofertility, genetic analysis, loans, and more In the aftermath of the Roe v. Wade overturn, U.S. fertility clinics (and patients alongside them) are battling an unlikely complication in ... |
| 07.07.2022 | BREAKING: Fyto lands $15m to grow aquatic “superplants” for animal feed and beyond | Disclosure: AFN’s parent company, AgFunder, is an investor in Fyto. US-based agtech startup Fyto has raised $15 million in Series A funding for its specialized aquatic “superplants” that can be used for animal feed, food and soil health ing... |
| 07.07.2022 | The Week in Agrifoodtech: Green Generation Fund raises $120m, Amazon takes Grubhub stake | This week, Germany’s Green Generation Fund landed more capital to invest in alt-protein startups, while Israeli foodtech firm Phytolon scored funding for its natural food coloring tech. In the food delivery realm, Amazon bought a stake in G... |
| 16.12.2021 | BREAKING: Phytoform bags $5.7m to boost crop resilience through genome edits | Agtech startup Phytoform Labs has raised a $5.7 million Seed round of funding to scale up its AI-based plant genome-editing platform. Seed-stage investor Eniac Ventures led the round. Wireframe Ventures, Fine Structure Ventures, FTW Venture... |
| 16.12.2021 | Phytoform bags $5.7m to boost crop resilience through genome edits | Agtech startup Phytoform Labs has raised a $5.7 million Seed round of funding to scale up its AI-based plant genome-editing platform. Seed-stage investor Eniac Ventures led the round. Wireframe Ventures, Fine Structure Ventures, FTW Venture... |
| 14.12.2021 | Ophelia Raises $50M to Expand Its Novel Approach to Opioid Addiction Treatment | What You Should Know: – Ophelia announced its $50 million Series B funding round, led by Tiger Global to expand access to medication-assisted treatment (the CDC’s recommended first-line treatment) to more people with opioid use disorder. – ... |
| 04.12.2020 | Backed by Khosla Ventures, Rubedo Life Sciences Secures $12M for Drug Discovery Platform | What You Should Know: – Biopharma startup Rubedo Life Sciences raises $12M to develop a broad portfolio of innovative therapies engineered to target cells for chronic age-related diseases. – Rubedo’s proprietary ALEMBIC™ drug discovery plat... |
Show more